Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
EUROMALVAC1
MALARIA
Framework programme: 5
Project number:
QLK2-CT-1999-01293
EC contribution: € 3 500 000
Duration: 36 months
Type: RS
Starting date: 1 February 2000
Website: http://www.euromalvac.org/profiles/klinkert.htm
Graphic element A European Malaria Vaccine Development Consortium
Keywords: Malaria; vaccine; development

Summary:

The EUROMALVAC consortium, working in 13 laboratories in six European countries, is developing malaria vaccines inducing protective antibody responses to Plasmodium falciparum bloodstage antigens, moving leading vaccine candidates towards GMP-production and clinical trial whilst validating second and third generation candidates in its malaria vaccine R&D pipeline.

Problem:

Malaria is the most widespread vector-borne disease of humans. It is caused by protozoa (small single-celled organisms) of the genus Plasmodium, which are transmitted by the bite of infected mosquitoes. For humans, the most severe forms of the disease are caused by the species Plasmodium falciparum

There is an urgent need to develop new methods to control malaria. Mosquito control and drug therapy have been the major tools used to date, but insecticide resistance and parasite resistance to cheap, and once effective, anti-malarial compounds pose a major threat. There is no vaccine available, despite good evidence that the human body's immune system can eventually control the disease and protect against new infections in those that survive the first infection.

Aim:

The project’s mission is to understand how the parasite can grow within its vertebrate host and how the host's immune system can control this growth. This new knowledge forms the basis on which vaccines can be developed.

The objectives are:

  • pre-clinical development and testing of Plasmodium falciparum Merozoite Surface Protein 1 (MSP-1) C-terminal-based vaccines with alum and new experimental adjuvants
  • defining the binding sites and biological activities of specific antibodies, thus designing more effective vaccine constructs using immunological and biochemical assays correlated with immunity
  • identifying cross-reactive epitopes, high-frequency variants and mapping epitopes of PfEMP-1
  • inducing antibodies against defined PfEMP-1 epitopes and determining whether specific human antibody responses to defined epitopes are associated with protection against disease
  • carrying out codon re-engineering and scaled up Pichia pastoris expression of P. falciparum AMA-1 constructs to obtain pure antigen for vaccine challenge studies in animal models
  • scaling-up production of Pf antigen R23 for vaccine formulation with alum and other adjuvants and dose-response experiments in animal models
  • collating the consortium's sera and parasite isolate banks to perform immuno-epidemiological services for all relevant consortium projects
  • preparing the malaria vaccine testing facility at Nijmegen University to carry out clinical trials of malaria vaccines.

Expected results:

The EUROMALVAC consortium has brought PfMSP-119 and PfAMA-1 vaccines close to clinical trial and has developed an experimental PfEMP-1 vaccine. It is hoped to develop second-generation vaccines for clinical trials and an effective malaria vaccine capable of inducing protective antibody responses to bloodstage parasite antigens.

Potential applications:

There are 400 million cases of malaria annually in sub-Saharan Africa with over 2 million deaths, particularly amongst children, pregnant women and migratory populations. The control of malaria would significantly benefit both the medical and economic health of the population of Africa and those in many other parts of the world.

Coordinator:

David Arnot
University of Edinburgh
ICAPB, Ashworth Laboratories, The King's Buildings
West Mains Road
EH9 3JT Edinburgh
United Kingdom
Tel: +44 131 650 8655
Fax: +44 131 650 8655
E-mail: d.e.arnot@ed.ac.uk
Website: http://helios.bto.ed.ac.uk/icapb/

Admin: Florance Kennedy
E-mail: f.k.kennedy@ed.ac.uk
Website: http://www.euromalvac.org/

Partners:

Principal
Scientific
Participants
Official Address Other Information
2Tony HolderMedical Research Council
Division of Parasitology
National Institute for Medical Research
The Ridgeway, Mill Hill
UK-NW7 1AA London
United Kingdom
Tel: +44 208 959 3666/2175
Fax: +44 208 913 8593
E-mail: aholder@nimr.mrc.ac.uk
Website: http://www.mrc.ac.uk/
3Thor TheanderUniversity of Copenhagen
Centre for Medical Parasitology
Panum Building 24.2, Blegdamsvej 3
DK–2200 Copenhagen N
Denmark
Tel: +45 35 327677
Fax: +45 35 327851
E-mail: theander@biobase.dk
Website: http://www.cmp.dk
4Graham Bentley, Odile Puijalon and Shirley LongacreInstitut Pasteur
Unite d'Immunologie Structurale
25 Rue du Docteur Roux
FR-75724 Paris
France
Tel: +33 1 45 68 86 10
Fax: +33 1 45 68 86 39
E-mail: bentley@pasteur.fr
Website: http://www.pasteur.fr/externe
E-mail: omp@pasteur.fr
Tel: +33 1 45 68 86 23
Fax: +33 1 40 61 35 84
Email: longacre@pasteur.fr
Tel: +33 1 40 61 35 49
Fax: +33 1 45 68 84 32
5Alan ThomasBiomedical Primate Research Centre
PO Box 3306
NL-2280 GJ Rijswijk
The Netherlands
Tel: +31 15 284 2538
Fax: +31 15 284 3986
E-mail: thomas@bprc.nl
Website: http://www.bprc.nl
6Graham MitchellKing's College London
3rd Floor, New Guy's House, Guy's Hospital
St Thomas' Street
UK-SE1 9RT London
United Kingdom
Tel: +44 207 955 4421
Fax: +44 207 955 8894
E-mail: g.h.mitchell@kcl.ac.uk
Website: http://www.kcl.ac.uk/
7Robert SauerweinUniversity Hospital, Nijmegen
Faculty of Medical Sciences
PO Box 9101
NL- 6500 HB Nijmegen
The Netherlands
Tel: +31 24 361 0577
Fax: +31 24 361 4666
E-mail: r.sauerwein@mmb.azn.nl
Website: http://www.umcn.nl/
8Mo KlinkertEberhard-Karls-Universitat, Tubingen
Sektion Humanparasitologie
Wilhelmstrasses 27
DE-72074Tubingen
Germany
Tel: +49 7071 298 0240
Fax: +49 7071 295 189
E-mail: mo.klinkert@uni-tuebingen.de
Website: http://www.uni-tuebingen.de
9David ConwayLondon School of Hygiene and Tropical Medicine
Keppel Street
Keppel Street
UK-WC1E 7HT London
United Kingdom
Tel: +44 207 927 2331
Fax: +44 207 636 8739
E-mail: david.conway@lshtm.ac.ukhttp
Website: http://www.lshtm.ac.uk/research/areas/#amal
10Mats WahlgrenKarolinska Institute, Stockholm
Department of Parasitology, Mycology and Environmental Microbiology
Nobels vag 18
SE-171 82 Solna
Sweden
Tel: +46 8 728 7277
Fax: +46 8 310 525
E-mail: mats.wahlgren@smi.ki.se
Website: http://info.ki.se/

 
 
top
Graphic element